Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Bioequivalence of Hana Loxoprofen Sodium Tablet to Dongwha Loxonin® Tablet (Loxoprofen Sodium 60 mg)

  • Kang, Hyun-Ah (Pharmaceutical Research Institutd, CJ Cheiljedang Corp.) ;
  • Cho, Hea-Young (Clinical Trials Management Division, Korea Food and Drug Administration) ;
  • Lee, Yong-Bok (Institute of Bioequivalence and Bridging Study, College of Pharmacy, Chonnam National University)
  • Received : 2011.03.25
  • Accepted : 2011.04.18
  • Published : 2011.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

Loxoprofen sodium, a 2-phenylpropionate non-steroidal anti-inflammatory drug (NSAID), has marked analgesic and antipyretic activities and relatively weak gastrointestinal ulcerogenicity. The purpose of the present study was to evaluate the bioequivalence of two loxoprofen sodium tablets, Hana loxoprofen sodium tablet (Hana Pharm. Co., Ltd.) and Dongwha Loxonin$^{(R)}$ tablet (Dongwha Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The in vitro release of loxoprofen from the two loxoprofen sodium formulations was tested using KP IX Apparatus II method with various dissolution media. Twenty four healthy Korean male volunteers, $22.83{\pm}1.862$ years in age and $69.92{\pm}9.14$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ crossover study was employed. After a single tablet containing 60 mg as loxoprofen sodium was orally administered, blood samples were taken at predetermined time intervals and the concentrations of loxoprofen in serum were determined using a online column-switching HPLC method with UV/Vis detection. The dissolution profiles of two formulations were similar in all tested dissolution media. The pharmacokinetic parameters such as $AUC^t$, $C_{max}$ and $T_{max}$ were calculated, and computer programs (Equiv Test and K-BE Test 2002) were utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$, $C_{max}$ and un-transformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug, Dongwha Loxonin$^{(R)}$ tablet, were 2.03, 2.99 and -9.49% for $AUC_t$, $C_{max}$, and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log0.8 to log1.25 (e.g., log0.9831~log1.0535 and log0.9455~log1.1386 for $AUC_t$ and $C_{max}$, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Hana loxoprofen sodium tablet was bioequivalent to Dongwha Loxonin$^{(R)}$ tablet.

Keywords

References

  1. Cho, H.Y., Park, C.H., Lee, Y.B., 2006. Direct and simultaneous analysis of loxoprofen and its diastereometric alcohol metabolites in human serum by on-line column switching liquid chromatography and its application to a pharmacokinetic study. J. Chromatogr. 835, 27-34. https://doi.org/10.1016/j.jchromb.2006.02.058
  2. Fan, G.R., Li, Z., Tang, S.X., Yang, H.C., Hu, J.H., 2003. Study on pharmacokinetics of loxoprofen tablets in healthy volunteers. Chin. J. New Drugs. Clin. Remed. 22, 22-24.
  3. KFDA, 2009. Guideline for Korean Good Clinical Practice 2009-211.
  4. KFDA, 2010. Guideline for Bioequivalence Test 2010-89.
  5. Kim, S.J., Oh, I.J., Shin, S.C., Lee, Y.B., Joh, H.N., Suh, S.P., 1997. Bioequivalence of loxoprofen tablets. Kor. J. Clin. Pharm. 7, 73-80
  6. Lee, Y.J., Kim, Y.G., Lee, M.G., Chung, S.J., Lee, M.H. and Shim, C.K., 2000. Analysis of bioequivalence study using log-transformed model. Yakhakhoeji. 44, 308-314.
  7. Matsuda, K., Tanaka, Y., Ushiyama, S., Ohnishi, K., Yamazaki, M., 1984. Inhibition of prostaglandin synthesis by sodium 2-[4-(2-oxocyclopentylmethyl)phenyl] propionate dihydrate (CS-600), a new anti-inflammatory drug, and its active metabolite in vitro and in vivo. Biochem. Pharmacol. 33, 2473-2478. https://doi.org/10.1016/0006-2952(84)90720-2
  8. Riendeau, D., Salem, M., Styhler, A., Ouellet, M., Mancini, J.A., Li, C.S., 2004. Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg. Med. Chem. Lett. 14, 1201-1203. https://doi.org/10.1016/j.bmcl.2003.12.047
  9. Statistical Solutions Ltd., 2001. Equiv $Test^{(R)}$ 2.0.
  10. Sugimoto, M., Kojima, T., Asami, M., Iizuka, Y., Matsuda, K., 1991. Inhibition of prostaglandin production in the inflammatory tissue by loxoprofen-Na, an anti-inflammatory prodrug. Biochem. Pharmacol. 42, 2363-2368. https://doi.org/10.1016/0006-2952(91)90242-W
  11. Terada, A., Naruto, S., Wachi, K., Tanaka, S., Iizuka, Y., Misaka, E., 1984. Synthesis and antiinflammatory activity of [(cycloalkylmethyl) phenyl]acetic acids and related compounds. J. Med. Chem. 27, 212-216. https://doi.org/10.1021/jm00368a019
  12. The Korean Pharmacopoeia IX(KP IX), 2007.

Cited by

  1. Fabrication and Analysis of Hydroxypropylmethyl Cellulose and Pectin-Based Controlled Release Matrix Tablets Loaded with Loxoprofen Sodium vol.34, pp.3, 2014, https://doi.org/10.1002/adv.21493